A poor metabolizer for cytochromes P450 2D6 and 2C19: A case report on antidepressant treatment

Maria Johnson, Courtney Markham-Abedi, Margaret T. Susce, Elaina Murray-Carmichael, Stuart McCollum, Jose De Leon

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Scientific literature has never described a poor metabolizer for both the cytochrome P450 (CYP) 2D6 and the CYP 2C19. They are expected to be rare (<1% in different ethnic groups) and prone to adverse drug reactions with many antidepressants. In an ongoing pharmacogenetic study, after genotyping 1,576 subjects in three Kentucky state hospitals we have found one poor metabolizer for both CYP 2D6 and CYP 2C19, which corresponds to a prevalence of 0.06% (95% CI 0.01 to 0.36). The naturalistic antidepressant treatment of this poor metabolizer for both enzymes is described in this article. As genotyping reaches clinical practice, it will be interesting to prospectively establish whether mirtazapine is a reasonable choice as an antidepressant for these patients, as the data and this case suggest.

Original languageEnglish
Pages (from-to)757-760
Number of pages4
JournalCNS Spectrums
Volume11
Issue number10
DOIs
StatePublished - Oct 2006

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'A poor metabolizer for cytochromes P450 2D6 and 2C19: A case report on antidepressant treatment'. Together they form a unique fingerprint.

Cite this